145 related articles for article (PubMed ID: 38516268)
21. Whole-Genome Expression Microarray Combined with Machine Learning to Identify Prognostic Biomarkers for High-Grade Glioma.
Shu C; Wang Q; Yan X; Wang J
J Mol Neurosci; 2018 Apr; 64(4):491-500. PubMed ID: 29502292
[TBL] [Abstract][Full Text] [Related]
22. Whole-exome sequencing identifies ATRX mutation as a key molecular determinant in lower-grade glioma.
Kannan K; Inagaki A; Silber J; Gorovets D; Zhang J; Kastenhuber ER; Heguy A; Petrini JH; Chan TA; Huse JT
Oncotarget; 2012 Oct; 3(10):1194-203. PubMed ID: 23104868
[TBL] [Abstract][Full Text] [Related]
23. Interplay between ATRX and IDH1 mutations governs innate immune responses in diffuse gliomas.
Hariharan S; Whitfield BT; Pirozzi CJ; Waitkus MS; Brown MC; Bowie ML; Irvin DM; Roso K; Fuller R; Hostettler J; Dharmaiah S; Gibson EA; Briley A; Mangoli A; Fraley C; Shobande M; Stevenson K; Zhang G; Malgulwar PB; Roberts H; Roskoski M; Spasojevic I; Keir ST; He Y; Castro MG; Huse JT; Ashley DM
Nat Commun; 2024 Jan; 15(1):730. PubMed ID: 38272925
[TBL] [Abstract][Full Text] [Related]
24. Frequent ATRX, CIC, FUBP1 and IDH1 mutations refine the classification of malignant gliomas.
Jiao Y; Killela PJ; Reitman ZJ; Rasheed AB; Heaphy CM; de Wilde RF; Rodriguez FJ; Rosemberg S; Oba-Shinjo SM; Nagahashi Marie SK; Bettegowda C; Agrawal N; Lipp E; Pirozzi C; Lopez G; He Y; Friedman H; Friedman AH; Riggins GJ; Holdhoff M; Burger P; McLendon R; Bigner DD; Vogelstein B; Meeker AK; Kinzler KW; Papadopoulos N; Diaz LA; Yan H
Oncotarget; 2012 Jul; 3(7):709-22. PubMed ID: 22869205
[TBL] [Abstract][Full Text] [Related]
25. ATRX/EZH2 complex epigenetically regulates FADD/PARP1 axis, contributing to TMZ resistance in glioma.
Han B; Meng X; Wu P; Li Z; Li S; Zhang Y; Zha C; Ye Q; Jiang C; Cai J; Jiang T
Theranostics; 2020; 10(7):3351-3365. PubMed ID: 32194873
[No Abstract] [Full Text] [Related]
26. Germline-driven replication repair-deficient high-grade gliomas exhibit unique hypomethylation patterns.
Dodgshun AJ; Fukuoka K; Edwards M; Bianchi VJ; Das A; Sexton-Oates A; Larouche V; Vanan MI; Lindhorst S; Yalon M; Mason G; Crooks B; Constantini S; Massimino M; Chiaravalli S; Ramdas J; Mason W; Ashraf S; Farah R; Van Damme A; Opocher E; Hamid SA; Ziegler DS; Samuel D; Cole KA; Tomboc P; Stearns D; Thomas GA; Lossos A; Sullivan M; Hansford JR; Mackay A; Jones C; Jones DTW; Ramaswamy V; Hawkins C; Bouffet E; Tabori U
Acta Neuropathol; 2020 Nov; 140(5):765-776. PubMed ID: 32895736
[TBL] [Abstract][Full Text] [Related]
27. New Molecular Considerations for Glioma: IDH, ATRX, BRAF, TERT, H3 K27M.
Karsy M; Guan J; Cohen AL; Jensen RL; Colman H
Curr Neurol Neurosci Rep; 2017 Feb; 17(2):19. PubMed ID: 28271343
[TBL] [Abstract][Full Text] [Related]
28. ATRX in Diffuse Gliomas With its Mosaic/Heterogeneous Expression in a Subset.
Purkait S; Miller CA; Kumar A; Sharma V; Pathak P; Jha P; Sharma MC; Suri V; Suri A; Sharma BS; Fulton RS; Kale SS; Dahiya S; Sarkar C
Brain Pathol; 2017 Mar; 27(2):138-145. PubMed ID: 26833422
[TBL] [Abstract][Full Text] [Related]
29. Cell-free circulating tumor DNA in patients with high-grade glioma as diagnostic biomarker - A guide to future directive.
Ahmed KI; Govardhan HB; Roy M; Naveen T; Siddanna P; Sridhar P; Suma MN; Nelson N
Indian J Cancer; 2019; 56(1):65-69. PubMed ID: 30950448
[TBL] [Abstract][Full Text] [Related]
30. Correlation Between Immunohistochemistry and Sequencing in H3G34-Mutant Gliomas.
Gianno F; Antonelli M; Di Dio T; Minasi S; Donofrio V; Buccoliero AM; Gardiman MP; Pollo B; Diomedi Camassei F; Rossi S; Novello M; Giangaspero F; Arcella A; Gessi M; Buttarelli FR
Am J Surg Pathol; 2021 Feb; 45(2):200-204. PubMed ID: 33428336
[TBL] [Abstract][Full Text] [Related]
31. PI3 kinase mutations and mutational load as poor prognostic markers in diffuse glioma patients.
Draaisma K; Wijnenga MM; Weenink B; Gao Y; Smid M; Robe P; van den Bent MJ; French PJ
Acta Neuropathol Commun; 2015 Dec; 3():88. PubMed ID: 26699864
[TBL] [Abstract][Full Text] [Related]
32. Alternative lengthening of telomeres is the major telomere maintenance mechanism in astrocytoma with isocitrate dehydrogenase 1 mutation.
Ferreira MSV; Sørensen MD; Pusch S; Beier D; Bouillon AS; Kristensen BW; Brümmendorf TH; Beier CP; Beier F
J Neurooncol; 2020 Mar; 147(1):1-14. PubMed ID: 31960234
[TBL] [Abstract][Full Text] [Related]
33. Molecular and histologic characteristics of pseudoprogression in diffuse gliomas.
Lin AL; White M; Miller-Thomas MM; Fulton RS; Tsien CI; Rich KM; Schmidt RE; Tran DD; Dahiya S
J Neurooncol; 2016 Dec; 130(3):529-533. PubMed ID: 27704386
[TBL] [Abstract][Full Text] [Related]
34. An immune signature to predict the prognosis of
Cao W; Sun P; Luo S; Zeng Z; Xiao C; Yu W; Lei S
Aging (Albany NY); 2023 Oct; 15(19):10453-10472. PubMed ID: 37812190
[TBL] [Abstract][Full Text] [Related]
35. Anti-angiogenic therapy for high-grade glioma.
Ameratunga M; Pavlakis N; Wheeler H; Grant R; Simes J; Khasraw M
Cochrane Database Syst Rev; 2018 Nov; 11(11):CD008218. PubMed ID: 30480778
[TBL] [Abstract][Full Text] [Related]
36. Transcriptomic Landscape of Lower Grade Glioma Based on Age-Related Non-Silent Somatic Mutations.
Park Y; Park J; Ahn JW; Sim JM; Kang SJ; Kim S; Hwang SJ; Han SH; Sung KS; Lim J
Curr Oncol; 2021 Jun; 28(3):2281-2295. PubMed ID: 34205437
[TBL] [Abstract][Full Text] [Related]
37. Reliability of IDH1-R132H and ATRX and/or p53 immunohistochemistry for molecular subclassification of Grade 2/3 gliomas.
Nishikawa T; Watanabe R; Kitano Y; Yamamichi A; Motomura K; Ohka F; Aoki K; Hirano M; Kato A; Yamaguchi J; Maeda S; Kibe Y; Saito R; Wakabayashi T; Kato Y; Sato S; Ogino T; Natsume A; Ito I
Brain Tumor Pathol; 2022 Jan; 39(1):14-24. PubMed ID: 34826036
[TBL] [Abstract][Full Text] [Related]
38. Immunohistochemistry on IDH 1/2, ATRX, p53 and Ki-67 substitute molecular genetic testing and predict patient prognosis in grade III adult diffuse gliomas.
Takano S; Ishikawa E; Sakamoto N; Matsuda M; Akutsu H; Noguchi M; Kato Y; Yamamoto T; Matsumura A
Brain Tumor Pathol; 2016 Apr; 33(2):107-16. PubMed ID: 26968173
[TBL] [Abstract][Full Text] [Related]
39. ATRX immunostaining predicts IDH and H3F3A status in gliomas.
Ebrahimi A; Skardelly M; Bonzheim I; Ott I; Mühleisen H; Eckert F; Tabatabai G; Schittenhelm J
Acta Neuropathol Commun; 2016 Jun; 4(1):60. PubMed ID: 27311324
[TBL] [Abstract][Full Text] [Related]
40. Prognostic factors in progressive high-grade glial tumors treated with systemic approach: A single center experience.
Alan O; Telli TA; Tuylu TB; Arikan R; Demircan NC; Ercelep O; Kaya S; Babacan NA; Atasoy BM; Bozkurt S; Bayri Y; Gul D; Ekinci G; Ziyal I; Dane F; Yumuk PF
J Oncol Pharm Pract; 2021 Mar; 27(2):329-339. PubMed ID: 32349641
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]